A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)
Clinical trial NCT04379271 · COMPLETED
Trial details
- NCT number
- NCT04379271
- Sponsor
- Immunic AG
- Status
- COMPLETED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-11
- Primary completion
- 2021-01-12
- Enrollment
- 234
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.